Stock XSPRAY XSPRAY PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

All News Xspray Pharma AB

Equities

XSPRAY

SE0009973563

Market Closed - Nasdaq Stockholm
Other stock markets
 11:12:39 2024-05-02 am EDT 		5-day change 1st Jan Change
40.95 SEK +1.11% Intraday chart for Xspray Pharma AB +0.74% +2.38%
Feb. 14 Xspray Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Feb. 12 US FDA Accepts Xspray Pharma's Refiled Application for Potential Leukemia Treatment MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Xspray Pharma Announces Fourth Product Candidate, targeting USD 2.3 billion Market
AQ
Xspray Pharma receives declaration of intent from Östersjöstiftelsen regarding exercise of TO6 warrants
AQ
Important information to holders of warrants series TO6: subscription period begins today
AQ
Notice of annual general meeting of Xspray Pharma AB (publ)
AQ
Xspray Pharma receives declarations of intent from its largest owners regarding exercise of TO6 warrants
AQ
Xspray Pharma publishes its Annual Report 2023
AQ
Xspray Pharma Q4 2023 - NDA-resubmission accepted by the FDA
AQ
Interim Report Fourth Quarter 2023
AQ
Xspray Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
FDA Accepts Xspray Pharma's NDA-resubmission for Dasynoc, PDUFA Date set to 31 July
AQ
FDA Accepts Xspray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31 July 2024
BU
US FDA Accepts Xspray Pharma's Refiled Application for Potential Leukemia Treatment
MT
FDA Accepts Xpray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31 July
AQ
FDA Accepts Xpray Pharma's NDA-Resubmission for Dasynoc® - PDUFA
CI
Xspray Pharma appoints Michael af Winklerfelt as acting CFO
AQ
Xspray Pharma AB Appoints Kerstin Hasselgren as Head of IR
CI
Xspray Pharma AB Announces CFO Changes
CI
New number of shares and votes in Xspray Pharma
AQ
Xspray Pharma raises SEK 92.3 million through warrants TO5
AQ
Xspray Pharma's XS003 Achieves Superior Bioavailability Milestone, Matching TASIGNA at Reduced Dosage
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XSPRAY Stock
  4. News Xspray Pharma AB